Recurrence risk after first febrile seizure and effect of short term diazepam prophylaxis

F URSIN KNUDSEN
Department of Paediatrics, Glostrup University Hospital, Denmark

SUMMARY In a prospective randomised study, 289 children admitted consecutively to hospital with their first febrile seizure were allocated, by date of admission, to short term diazepam prophylaxis (n=152) or to no prophylaxis (n=137) and followed for 18 months. In untreated children, five major risk factors for recurrent febrile convulsions were identified: age 15 months or less at the time of the first febrile seizure, epilepsy in first degree relatives, febrile convulsions in first degree relatives, a first complex febrile seizure, and day nursery care. The 18 month recurrence rate was 80 to 100% if three or five risk factors were present, 50% if two factors were identified, 25% where one factor was found, and 12% if there were no predictors. During prophylaxis the recurrence rate was uniformly low (mean 12%) in all risk groups. In high (three or more factors) and intermediate (two factors) risk children prophylaxis provided effective seizure control and reduced the recurrence rate from 80%, or more, to 12% and 50% to 12%, respectively. In children with one risk factor 50% of all recurrences were prevented (25% to 12%). Prophylaxis was ineffective in very low risk children (12% to 12%).

In recent studies various risk factors for recurrent febrile convulsions have been identified.1-4 There is, however, little available evidence on the interaction of these risk factors and on their influence on the recurrence risk with or without prophylaxis.

In a prospective randomised study we investigated the efficacy of short term diazepam prophylaxis in 289 children referred consecutively to hospital with their first febrile seizure. The results from this study have already been reported.5-6 We have now identified major risk factors for recurrent febrile seizures in these 289 children, stratified the children according to the risk of a recurrence, and analysed the efficacy of prophylaxis in high, intermediate, and low risk children given either short term diazepam prophylaxis at times of fever for 18 months or no prophylaxis. Pharmacokinetic and clinical data on short term diazepam prophylaxis have also been reported elsewhere.7-8

Material and methods

Among 326 children referred consecutively to hospital during the period 1 June 1978 to 1 June 1980 with their first simple or complex febrile seizure, 289 were included in the study as they lived in our referral area of Copenhagen. Exclusion criteria were purulent meningitis, chronic cerebral disease, or a history of non-febrile seizures. Subject to their parents’ informed consent the children were allocated by date of admission either to short term diazepam prophylaxis (even dates) for 18 months, that is rectal diazepam in solution (Apozepam, Apothekernes Laboratorium for Specialpreparater, Norway) 5 mg (3 years, or less) to 7.5 mg (3 or more years) at time of illness (when the temperature was 38.5°C or more) or to the control group (odd dates) given no prophylaxis and only rectal diazepam in case of further fits. In the prophylaxis group all parents were told to administer diazepam rectally whenever the child had a temperature of 38.5°C or more, and to repeat the treatment every 12 hours until the temperature fell below 38.5°C. After finishing the present study we have changed our routine prophylaxis slightly. To avoid unnecessary sedation due to accumulation of diazepam a maximum of four consecutive doses are given per illness.

The patients were seen in the outpatient clinic, 3, 6, 12, and 18 months after the first febrile seizure, and an electroencephalograph was obtained one month after the first febrile seizure. The total follow up period, with cut off at 18 months, was 2406 months in the prophylaxis group and 2093 months in the control group. A total of 29 children (10%) were
followed for 0 to 3 months, 19 (6%) for 3 to 11 months, 45 (16%) for 12 to 17 months and 196 (68%) for 18 months or more.

The variables analysed simultaneously by Cox's multivariate step-wise regression analysis were: sex; age at the first febrile seizure; febrile convulsions in parents or siblings; epilepsy in parents or siblings; type of first febrile seizure, that is simple or complex (15 minutes or more, and/or focal and/or multiple, two or more fits per 24 hours); child care (home, day care, day nursery); and psychomotor development (normal, slightly retarded). The estimated recurrence rates were corrected for the varying follow up periods, that is to the values had all patients been followed throughout the 18 months' period. Only the first recurrence was taken into account in Cox's analysis.

The prophylaxis and control groups were stratified according to the number of risk factors identified in the individual child (0-5 items) into six groups, two low risk groups (none or one factor), an intermediate group (two factors), and three high risk groups (three, four, or five factors) (Table 1). Risk group 0 included children aged more than 15 months with simple febrile seizures without a family history of epilepsy or febrile convulsions, and cared for at home. Children in risk group 5 comprised all five factors: young age (15 months or less), a complex first febrile seizure, a positive family history of both epilepsy and febrile seizures, and day nursery care.

Results

Clinical data. The prophylaxis group (n=152) consisted of 78 boys and 74 girls. A total of 140 (93%) had had a short lasting (less than 15 minutes) and 12 (7%) a long lasting (15 minutes or more) seizure. Some 130 (86%) had had a simple and 22 (14%) a complex first febrile seizure. A total of 60 (40%) children were aged less than 15 months and 92 (60%) 15 months or more.

The control group (n=137) (Table 1) comprised 80 boys and 57 girls of whom 131 (96%) had had convulsions of short duration and 6 (4%) of long duration. Altogether 112 (82%) had had a simple and 25 (18%) a complex first seizure. No significant differences between the two groups were found in respect of sex, age, type and duration of convulsions, and family history of epilepsy and febrile convulsions.

The number of children with recurrences versus the total number of children in the stratified prophylaxis and control groups are given in Table 2.

Table 1 Recurrence rate in relation to identified risk factors in children given no prophylaxis

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Risk score</th>
<th>No of patients</th>
<th>Recurrence rate (% (SD))*</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;15 month</td>
<td>1</td>
<td>56</td>
<td>33 (6)</td>
<td>50 (7)</td>
</tr>
<tr>
<td>≥15 month</td>
<td>0</td>
<td>81</td>
<td>15 (4)</td>
<td>18 (5)</td>
</tr>
<tr>
<td>Epilepsy in the family:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1</td>
<td>8</td>
<td>59 (17)</td>
<td>59 (17)</td>
</tr>
<tr>
<td>No</td>
<td>0</td>
<td>129</td>
<td>20 (4)</td>
<td>30 (4)</td>
</tr>
<tr>
<td>Febrile convulsions in the family:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1</td>
<td>34</td>
<td>40 (9)</td>
<td>52 (9)</td>
</tr>
<tr>
<td>No</td>
<td>0</td>
<td>103</td>
<td>12 (4)</td>
<td>27 (5)</td>
</tr>
<tr>
<td>Type of first febrile convulsions:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complex</td>
<td>1</td>
<td>25</td>
<td>39 (10)</td>
<td>51 (10)</td>
</tr>
<tr>
<td>Simple</td>
<td>0</td>
<td>112</td>
<td>20 (4)</td>
<td>28 (5)</td>
</tr>
<tr>
<td>Care:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Home/day care</td>
<td>0</td>
<td>91</td>
<td>37 (7)</td>
<td>40 (7)</td>
</tr>
</tbody>
</table>

*P values and SD are derived from log rank test and Cox's analysis.

Table 2 Number of children with seizure recurrence within 18 months v the total number of children, stratified according to the number of risk factors identified

<table>
<thead>
<tr>
<th>No of risk factors</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4-5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Control group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children with recurrences (n=46)</td>
<td>4 (11%)</td>
<td>14 (26%)</td>
<td>16 (46%)</td>
<td>9 (82%)</td>
<td>3 (100%)</td>
</tr>
<tr>
<td>Total no of children (n=137)</td>
<td>35</td>
<td>53</td>
<td>35</td>
<td>11</td>
<td>3</td>
</tr>
<tr>
<td><strong>Prophylaxis group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children with recurrences (n=19)</td>
<td>4 (9%)</td>
<td>11 (17%)</td>
<td>3 (10%)</td>
<td>1 (13%)</td>
<td>0</td>
</tr>
<tr>
<td>Total no of children (n=152)</td>
<td>46</td>
<td>66</td>
<td>31</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Total no of children (n=289)</td>
<td>81 (28%)</td>
<td>118 (40%)</td>
<td>66 (24%)</td>
<td>19 (7%)</td>
<td>4 (1%)</td>
</tr>
</tbody>
</table>
Recurrence risk after first febrile seizure and effect of short term diazepam prophylaxis

The age distribution did not differ significantly in the major risk groups (P=0:1).

Risk factors in untreated children. Five major risk factors for subsequent febrile convulsions could be identified (Table 1). Early age at the time of the first febrile seizure was the variable most highly associated with recurrences. The age dependent risk was identified in many models, but was most noticeable by an age division at 15 months at the onset of the initial seizure.

In a model excluding the influence of the child’s age, multivariate regression analysis identified four additional factors (Table 1), which per se significantly contributed to the recurrence risk: a history of epilepsy in first degree relatives, a history of febrile convulsions in first degree relatives, a first complex febrile seizure, and nursery care. Sex (P=0.2) and psychomotor development (P=0.2) did not significantly contribute to the recurrence risk.

Risk factors during prophylaxis. Prophylaxis eliminated all risk factors, except a first complex febrile seizure. Children with complex febrile seizure receiving diazepam at times of fever carried a high 18 months recurrence risk compared with children with simple febrile seizures (55% v 27%, P<0.05).

Assessment of recurrence risk. In the untreated group, high (three or more factors), intermediate (two factors), and low risk children (none or one factor) could be identified. The 18 month recurrence rate was 80 to 100% if three to five risk factors were identified, 50% if two factors were present, 25% for one factor, and 12% in children without any risk factors (Fig. 1).

During prophylaxis the recurrence rate was uniformly low (mean 12%) in all risk groups (Fig. 2).

The reduction in the recurrence risk associated with prophylaxis (Figs. 1 and 2) was strongly influenced by the number of predictors. In high and intermediate risk children, prophylaxis afforded effective seizure control and reduced the recurrence rate from 80% or more to 12% and from 50% to 12%, respectively. In low risk children, comprising 40%, 50% of all the recurrences were prevented (25% to 12%), whereas very low risk children (28% of the study group) did not respond to prophylaxis (12% to 12%).

The predictive value of the best positive or negative answer to the question of whether an individual child would have another febrile seizure within 18 months is given in Table 3.

![Risk factors and recurrence risk without prophylaxis](image)

**Fig. 1** Risk factors and recurrence risk without prophylaxis.

Without prophylaxis low risk (0–1 risk factor), intermediate risk (2 risk factors), and high risk children (≥3 risk factors) could be identified. The recurrence rate is 12% in very low risk and 80 to 100% in high risk children after 18 months follow up.

![Risk factors and recurrence risk during prophylaxis](image)

**Fig. 2** Risk factors and recurrence risk during prophylaxis.

Prophylaxis with diazepam at times of fever eliminated the risk factors, except a first complex febrile convolution (not shown). The recurrence rate is uniformly low. Prophylaxis is ineffective in very low risk children.

**Table 3** Predictive value of the 18 months’ recurrence risk assessment in the untreated child, who has experienced a first febrile seizure

<table>
<thead>
<tr>
<th>No of risk factors</th>
<th>Actual outcome recurrence (%)</th>
<th>Predicted outcome recurrence, yes/no best guess</th>
<th>Prediction correct in % of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td>10</td>
<td>90</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>25</td>
<td>75</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>80</td>
<td>20</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Downloaded from http://adc.bmj.com/ on June 6, 2017 - Published by group.bmj.com
Discussion

The study indicates that at least five factors influence the seizure recurrence rate. Furthermore, the number of predictors identified in each child seems to be useful in identifying those who are likely to have further febrile seizures. It seems that each risk factor, whether genetic or environmental, contributes to the recurrence risk in a cumulative way; the more items identified the higher the recurrence rate.

In an effort to estimate the recurrence risk more accurately, a prognostic index based on a six point scale was established. For practical purposes weak and strong predictors were assigned equal predictive power. In terms of risk groups, the risk assessment seemed to be reliable and a fairly good correlation between predicted and actual outcome was obtained. Thus, populations at low, intermediate, and high risk of future febrile seizures could readily be identified by means of the proposed scoring system. There is no reason, however, to suggest that the occurrence of recurrent febrile convulsions could be accurately predicted in an individual child. The prediction seemed especially inaccurate in children belonging to the intermediate group. Moreover, genetic10-12 and probably socioeconomic factors may influence the type, number, interplay, and power of the predictors, and the items used to assess the recurrence risk in our study may not be appropriate for all geographical locations. Biased reporting of the family history and the type of convulsion may further reduce the predictive value.

Most studies, including ours, agree that early age at the time of the first febrile seizure is the most powerful predictor for subsequent febrile convulsions.1-4 10 In the perinatal collaborative study only two risk factors were identified—early age at the time of initial seizure and a history of epilepsy in the near family, whereas a complex first febrile seizure and sex were not related to the recurrence rate.4 13 Van den Berg did not find any other characteristics of the initial seizure related to recurrence rate.2 Wallace found that an initial complex seizure, a family history of epilepsy, and social class were significantly associated with high recurrence rate.3 14 The selection of sex as a risk factor10 12 may be related to a stratification bias and could not be confirmed in the collaborative or the present study.

Our recent study indicated that short term diazepam prophylaxis reduced the 18 month recurrence rate from 39% to 12% and thus prevented two thirds of all further febrile fits.5 Stratification showed a remarkably wide range of recurrence rates in untreated children, a uniformly low recurrence rate in response to diazepam prophylaxis at times of fever, and an appreciable difference in the efficacy of prophylaxis, in terms of risk reduction.

The National Institutes of Health consensus recommended that long term prophylaxis by phenobarbitone or valproic acid should be reserved for high risk children, that is a small group with a high risk of developing epilepsy.15 By giving a few doses of diazepam per year, however (an average of five in the Copenhagen area), effective seizure control and emotional stability in the family can be obtained7 10 without the many risks associated with long term prophylaxis.16-18 No serious side effects were observed from diazepam prophylaxis. In the prophylaxis group, the parents described mild, transient side effects in 65%: sedation (36%), euphoria (15%), ataxia (8%), aggressiveness (2%). One child (0-6%) had a dental fracture probably related to ataxia.6 The parents managed the treatment surprisingly well, and compliance problems were minimal, provided that careful instruction concerning administration procedures and side effects were given. Only 4% of the children in the prophylaxis group had a recurrent febrile seizure despite adequate prophylaxis. In only 4% of children allocated to prophylaxis a recurrence of febrile convulsions occurred because administration of diazepam was deliberately omitted by the parents.

The present study shows that the main effect of diazepam prophylaxis at times of fever is to provide effective seizure control in high and intermediate risk children, but that it is ineffective in the lowest risk group, comprising almost one third of the children. Our findings favour a selective prophylaxis policy,15 19 and the candidates for prophylaxis may be identified by means of the risk assessment model, based on factors readily obtainable in most children.

Supported by grants 12–2922 and 12–3674 from the Danish Medical Research Council.

I thank Svend Larsen, Herlev University Hospital, for performing the data processing and statistical analysis.

References
Recurrence risk after first febrile seizure and effect of short term diazepam prophylaxis


Correspondence to Dr F U Knudsen, Department of Paediatrics, Glostrup Hospital, DK 2600 Glostrup, Denmark.

Received 11 July 1985
Recurrence risk after first febrile seizure and effect of short term diazepam prophylaxis.

F U Knudsen

Arch Dis Child 1985 60: 1045-1049
doi: 10.1136/adc.60.11.1045

Updated information and services can be found at:
http://adc.bmj.com/content/60/11/1045

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/